

Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders olipudase alfa-rpcp (Xenpozyme)

INTRAVENOUS INFUSION FOR ADMINISTRATION BY A HEALTHCARE PROFESSIONAL

PRIOR REVIEW/CERTIFICATION REQUEST FOR SERVICES FORM

INCOMPLETE FORMS MAY DELAY PROCESSING

ALL NC PROVIDERS MUST PROVIDE THEIR 5-DIGIT Blue Cross NC PROVIDER ID# BELOW

PATIENT NAME		BLUE CROSS NC MEMBER ID NUMBER		PATIENT DATE OF BIRTH	
REQUESTING PROVIDER INFORMATION			SERVICING PROVIDER OR FACILITY LOCATION (for services to be performed outside of the physician office)		
Provider Name		Servicing Provider			
Provider #, Tax ID # or NPI		Facility Name			
Street, Bldg., Suite #		Servicing provider or Facility #, Tax ID # or NPI			
City/State/Zip code		Street, Bldg., Suite #			
Phone #		City/State/Zip code			
Fax #					
PLACE OF SERVICE: <input type="checkbox"/> Home <input type="checkbox"/> Office <input type="checkbox"/> Outpatient hospital <input type="checkbox"/> Specialty Pharmacy					
Specialty Pharmacy:			Specialty Pharmacy NPI:		
HCPCS CODE:			CPT/Other billing code:		
Primary Diagnosis:			ICD-10:		

Please answer the following questions for INITIAL coverage and submit medical record documentation:

See pages 3 for continuation coverage; see page 4 for quantity limit exceptions

1. Does the patient have a diagnosis of **acid sphingomyelinase deficiency (ASMD)** type A/B OR type B?..... Yes No
Please submit medical record documentation related to medical necessity criteria.
2. Does the patient have documented deficiency of acid sphingomyelinase as measured in peripheral leukocytes, cultured fibroblasts or lymphocytes?..... Yes No
3. Is the patient less than 18 years of age?..... Yes No
 - a. Does the patient have a spleen volume ≥ 5 multiple of normal (MN) measured by magnetic resonance imaging (MRI)?..... Yes No
 - b. Does the patient have acute or rapidly progressive neurological abnormalities?..... Yes No
 - c. Does the patient have a delay of gross motor skills?..... Yes No
4. Is the patient ≥ 18 years of age?..... Yes No
 - a. Does the patient have a spleen volume ≥ 6 multiple of normal (MN) measured by magnetic resonance imaging (MRI)?..... Yes No
 - b. Does the patient have a splenomegaly-related score (SRS) of ≥ 5 ?..... Yes No
 - c. Does the patient have a diffusing capacity of lung for carbon monoxide (DLCO) measurement $\leq 70\%$ of the predicted normal value?..... Yes No

****continued on page 2; sign page 2 for prior authorization request****

**Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders – *continued*
olipudase alfa-rpcp (Xenpozyme)**

5. Does the patient have any of the following conditions:
 - a. An active, serious, intercurrent illness?..... Yes No
 - b. Active hepatitis B or hepatitis C infection?..... Yes No
 - c. Infection with human immunodeficiency virus (HIV)?..... Yes No
 - d. Cirrhosis determined by clinical evaluation?..... Yes No
 - e. Clinically significant arrhythmia, moderate or severe pulmonary hypertension or valvular dysfunction, or < 40% left ventricular ejection fraction by echocardiogram?..... Yes No
 - f. Malignancy diagnosed with the previous 5 years other than non-melanoma skin cancer?..... Yes No
6. Does the patient have any central nervous system manifestations of acid sphingomyelinase deficiency (ASMD)?..... Yes No
7. Does the patient have a platelet count $\geq 60 \times 10^3/\mu\text{L}$?..... Yes No
8. Does the patient have an international normalized ratio (INR) < 1.5?..... Yes No
9. Does the patient have an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level < 250 IU/L?..... Yes No
 - a. **If NO**, does the patient have a total bilirubin level < 1.5mg/dL?..... Yes No
10. Has the patient had a major organ transplant (bone marrow or liver)?..... Yes No
11. Is the provider a specialist in the area of the patient’s diagnosis (e.g., Geneticist, Hepatologist, Pulmonologist)?..... Yes No
12. Will the injection or infusion of the requested medication be administered in an **inpatient or outpatient hospital setting**?..... Yes No
If YES, please answer the Site of Care questions on pages 5-6.
13. Is the requested quantity within the maximum units allowed (see table on page 6)?..... Yes No
If NO, please complete page 4 for a quantity limit exception.

Please certify the following by signing and dating below:

I certify that I have been authorized to request prior review and certification for the above requested service(s). I further certify that my patient’s medical records accurately reflect the information provided. I understand that Blue Cross NC may request medical records for this patient at any time in order to verify this information. I further understand that if Blue Cross NC determines this information is not reflected in my patient’s medical records, Blue Cross NC may request a refund of any payments made and/or pursue any other remedies available.

Prescriber’s Signature (Required): _____ **Date:** _____

For Blue Cross NC members, fax form to 1-888-348-7332

**Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders - CONTINUATION
olipudase alfa-rpcp (Xenpozyme)
INTRAVENOUS INFUSION FOR ADMINISTRATION BY A HEALTHCARE PROFESSIONAL**

PRIOR REVIEW/CERTIFICATION REQUEST FOR SERVICES FORM

INCOMPLETE FORMS MAY DELAY PROCESSING

ALL NC PROVIDERS MUST PROVIDE THEIR 5-DIGIT Blue Cross NC PROVIDER ID# BELOW

PATIENT NAME		BLUE CROSS NC MEMBER ID NUMBER	PATIENT DATE OF BIRTH
REQUESTING PROVIDER INFORMATION		SERVICING PROVIDER OR FACILITY LOCATION (for services to be performed outside of the physician office)	
Provider Name		Servicing Provider	
Provider #, Tax ID # or NPI		Facility Name	
Street, Bldg., Suite #		Servicing provider or Facility #, Tax ID # or NPI	
City/State/Zip code		Street, Bldg., Suite #	
Phone #		City/State/Zip code	
Fax #			
PLACE OF SERVICE: <input type="checkbox"/> Home <input type="checkbox"/> Office <input type="checkbox"/> Outpatient hospital <input type="checkbox"/> Specialty Pharmacy			
Specialty Pharmacy:		Specialty Pharmacy NPI:	
HCPCS CODE:		CPT/Other billing code:	
Primary Diagnosis:		ICD-10:	

Please answer the following questions for CONTINUATION coverage, and submit medical record documentation:

- Was the patient approved for initial coverage for the requested medication through Blue Cross NC?..... Yes No
If NO, please answer all questions on pages 1-2. If YES, please answer the following questions AND submit medical record documentation related to medical necessity criteria.
- Has the patient demonstrated clinical benefit since initiating therapy?..... Yes No
Please submit medical record documentation.
- Has the patient experienced disease stabilization since initiating therapy?..... Yes No
Please submit medical record documentation.
- Will the injection or infusion of the requested medication be administered in an **inpatient or outpatient hospital setting**?..... Yes No
If YES, please answer the Site of Care questions on pages 5-6.
- Is the requested quantity within the maximum units allowed (see table on page 6)?..... Yes No
If NO, please complete page 4 for a quantity limit exception.

Please certify the following by signing and dating below:

I certify that I have been authorized to request prior review and certification for the above requested service(s). I further certify that my patient's medical records accurately reflect the information provided. I understand that Blue Cross NC may request medical records for this patient at any time in order to verify this information. I further understand that if Blue Cross NC determines this information is not reflected in my patient's medical records, Blue Cross NC may request a refund of any payments made and/or pursue any other remedies available.

Prescriber's Signature (Required): _____ **Date:** _____

For Blue Cross NC members, fax form to 1-888-348-7332

**Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders
olipudase alfa-rpcp (Xenpozyme) - QUANTITY LIMIT EXCEPTION
INTRAVENOUS INFUSION FOR ADMINISTRATION BY A HEALTHCARE PROFESSIONAL**

PATIENT NAME		BLUE CROSS NC MEMBER ID NUMBER		PATIENT DATE OF BIRTH	
REQUESTING PROVIDER INFORMATION			SERVICING PROVIDER OR FACILITY LOCATION (for services to be performed outside of the physician office)		
Provider Name			Servicing Provider		
Provider #, Tax ID # or NPI			Facility Name		
Street, Bldg., Suite #			Servicing provider or Facility #, Tax ID # or NPI		
City/State/Zip code			Street, Bldg., Suite #		
Phone #			City/State/Zip code		
Fax #					
PLACE OF SERVICE: <input type="checkbox"/> Home <input type="checkbox"/> Office <input type="checkbox"/> Outpatient hospital <input type="checkbox"/> Specialty Pharmacy					
Specialty Pharmacy:			Specialty Pharmacy NPI:		
HCPCS CODE:			CPT/Other billing code:		
Primary Diagnosis:			ICD-10:		

FOR COVERAGE OVER THE FDA LABELED DOSING (SEE TABLE ON PAGE 6), PLEASE SELECT THE REQUESTED MEDICATION AND ANSWER THE FOLLOWING QUESTIONS:

Please note: This medication requires a prior authorization before a quantity limit override can be considered. Before submitting a request for a quantity level override, please ensure that a prior approval authorization has been submitted and/or approved (pages 1-2 or page 3). Otherwise, this request will deny.

Requested units: _____

****Please enter quantity as a numeric value with one decimal place (ex. 1.0, 1.5)****

Please provide the patient's current weight: _____ kg lbs

In the space provided, please document support for the requested Quantity Limit Exception (this may include documented clinical rationale and/or medical records).

Please certify the following by signing and dating below:

I certify that I have been authorized to request prior review and certification for the above requested service(s). I further certify that my patient's medical records accurately reflect the information provided. I understand that Blue Cross NC may request medical records for this patient at any time in order to verify this information. I further understand that if Blue Cross NC determines this information is not reflected in my patient's medical records, Blue Cross NC may request a refund of any payments made and/or pursue any other remedies available.

Prescriber's Signature (Required): _____ **Date:** _____

For Blue Cross NC members, fax form to 1-888-348-7332

**Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders – SITE OF CARE
olipudase alfa-rpcp (Xenpozyme)
INTRAVENOUS INFUSION FOR ADMINISTRATION BY A HEALTHCARE PROFESSIONAL**

PATIENT NAME		BLUE CROSS NC MEMBER ID NUMBER	PATIENT DATE OF BIRTH
REQUESTING PROVIDER INFORMATION		SERVICING PROVIDER OR FACILITY LOCATION (for services to be performed outside of the physician office)	
Provider Name		Servicing Provider	
Provider #, Tax ID # or NPI		Facility Name	
Street, Bldg., Suite #		Servicing provider or Facility #, Tax ID # or NPI	
City/State/Zip code		Street, Bldg., Suite #	
Phone #		City/State/Zip code	
Fax #			
PLACE OF SERVICE: <input type="checkbox"/> Home <input type="checkbox"/> Office <input type="checkbox"/> Outpatient hospital <input type="checkbox"/> Specialty Pharmacy			
Specialty Pharmacy:		Specialty Pharmacy NPI:	
HCPCS CODE:		CPT/Other billing code:	
Primary Diagnosis:		ICD-10:	

PLEASE SELECT THE REQUESTED MEDICATION AND ANSWER THE FOLLOWING QUESTIONS:

Please note: This medication requires a **prior authorization** before Site of Care can be considered. Before submitting a request for Site of Care, please ensure that a prior approval authorization has been submitted and/or approved (pages 1-2 or page 3). Otherwise, this request will deny.

1. Is the injection/infusion being administered in an **inpatient setting**?..... Yes No
If YES, please answer the following questions:
 - a. Is the sole purpose of the inpatient admission for giving the injection/infusion?..... Yes No
 - b. Is this an **emergent** admission/request (the patient presented to the hospital via emergency room or transferred inpatient from another facility)?..... Yes No

2. Is the injection/infusion being administered in an **outpatient hospital setting**?..... Yes No
If YES, please answer the following questions:
 - a. Does the patient have a history of mild adverse events that have not been successfully managed through mild pre-medication (e.g., diphenhydramine, acetaminophen, steroids, fluids, etc.)?..... Yes No
 - b. Is the patient unable to physically and cognitively adhere to the treatment schedule and regimen complexity?..... Yes No
 - c. Is the patient new to therapy (defined as initial injection/infusion OR less than 3 months since the initial injection/infusion)?..... Yes No
 - d. Is this the first injection/infusion after 6 months of no injections/infusions for medications with approved dosing intervals of less than 6 months?..... Yes No
 - e. Is this the first injection/infusion after at least a 1-month gap in therapy outside of the approved dosing interval for medications requiring every 6 months dosing duration?..... Yes No
 - f. Is this request required due to a change in formulation of the requested medication?..... Yes No

*****NOTE: continued on page 6, please sign page 6 for Site of Care request*****

**Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders – SITE OF CARE
olipudase alfa-rpcp (Xenpozyme)
INTRAVENOUS INFUSION FOR ADMINISTRATION BY A HEALTHCARE PROFESSIONAL**

Please certify the following by signing and dating below:

I certify that I have been authorized to request prior review and certification for the above requested service(s). I further certify that my patient's medical records accurately reflect the information provided. I understand that Blue Cross NC may request medical records for this patient at any time in order to verify this information. I further understand that if Blue Cross NC determines this information is not reflected in my patient's medical records, Blue Cross NC may request a refund of any payments made and/or pursue any other remedies available.

Prescriber's Signature (Required): _____ **Date:** _____

For Blue Cross NC members, fax form to 1-888-348-7332

FDA Label Reference					
Medication	Indication	Dosing		HCPCS	Maximum Units*
Olipudase alfa-rpcp (Xenpozyme®) intravenous (IV) infusion	Acid sphingomyelinase deficiency (ASMD)	Patients ≥ 18 years old: IV infusion every 2 weeks		C9399** J3490** J3590**	Patients ≥ 18 years old: 5,841 units Patients < 18 years old: 5,574 units
		Week 0	0.1 mg/kg		
		Weeks 2-4	0.3 mg/kg		
		Weeks 6-8	0.6 mg/kg		
		Week 10	1 mg/kg		
		Week 12	2 mg/kg		
		Week 14	3 mg/kg (Recommended maintenance dose)		
		Patients < 18 years old: IV infusion every 2 weeks			
		Week 0	0.03 mg/kg		
		Weeks 2	0.1 mg/kg		
		Weeks 4-6	0.3mg/kg		
		Weeks 8-10	0.6 mg/kg		
		Week 12	1 mg/kg		
		Week 14	2 mg/kg		
Week 16	3 mg/kg (Recommended maintenance dose)				

*Maximum units allowed for duration of approval

**Non-specific assigned HCPCS codes, must submit requested product NDC